Objectives. Major injury is a time-dependent illness in which the quantification of the life prognosis is fundamental for professionals. The objective of this study is to evaluate the capacity of prehospital lactic acid to predict mortality (2, 7 and 30 days) and the admission to the Intensive Care Unit (ICU) from the index event.
INTRODUCTION
Major injury (MI) represents the sixth cause of death and the fifth cause of disability worldwide, most frequently caused by traffic accidents and work accidents.1 Prehospital Emergency Medical Services (PEMS) have developed operational and functional procedures to manage this pathology quickly and efficiently, but even today, few diagnostic means exist in the prehospital setting. Point-of-care testing (POCT) is easy, safe and cheap. It includes the prehospital lactic acid (PLA) value2 as a very reliable indicator of anaerobic metabolism. [3] [4] MI is a time-dependent pathology, in which the early identification of gravity and potential evacuation to the most appropriate trauma centre may affect a decrease in morbidity and mortality. [5] [6] The main objective of this study is evaluating the capacity of the PLA to predict mortality (2, 7 and 30 days) and the admission to the Intensive Care Unit (ICU) from the index event.
MATERIAL & METHODS

Study design and setting
This is a longitudinal, prospective observational study, which included patients that were attended by an Advanced Life Support Unit (ALSU) in the city of Valladolid (Spain) and transferred to the Emergency Department (ED), between April 1 and September 30, 2018.
Study population
We considered that a patient met criteria to be included in the study if their pathology was of traumatic origin, had been transferred by an ALSU to the ED and did not meet any exclusion criteria, which were: being a minor, having non-traumatic pathology, cardiorespiratory arrest or death before or during the transfer (Figure 1 ).
Data collection
At the time of prehospital care, the PLA was determined in venous blood. To determine the levels of lactic acid, the Accutrend® Plus meter by Roche was used. Demographic variables (sex and age), epidemiological variables (aetiology and injury mechanism) and prehospital advanced life support manoeuvres were collected, which included use of supplementary oxygen, advanced airway management and use of intravenous medication. At the hospital level, we analysed the destination in the hospital (discharge or admission), the need for ICU, days of admission and mortality.
Outcome measures and analysis
The main outcome variable was mortality from any cause (2, 7 and 30 days). All data was stored in an XLSTAT® BioMED database for Microsoft Excel® (version 14.4.0.). The area under the curve (AUC) of the receiver operating characteristic (ROC) of the PLA was calculated in terms of mortality at 2, 7 and 30 days and for the need to enter ICU, as well as the best score that offered in each case greatest sensitivity and specificity. We also calculated for these scores the positive predictive value (PPV), negative predictive value (NPV), positive likelihood ratio (PLR) and negative likelihood ratio (NLR).
Ethical issues
The study was approved by the Ethical and Clinical Research Committees of all participating centres. All patients (or guardians) signed informed consent. The study was registered in the international clinical trials registry platform of the World Health Organization (doi.org/10.1186/IS-RCTN17676798).
RESULTS
A total of 109 patients were included in our study. The median age was 53 years (IQR: 40-68), 39 patients (35.8%) were women. The most frequent aetiology was traffic accidents in 55 cases (50.5%), and the most common injury mechanism was closed trauma in 95 cases (87.1%). The median PLA was 3.6 mmol/L (IQR: 2.6-5.1). Survivors had 3.3 mmol/L (IQR: 2.4-4.3), versus 5.9 mmol/L (IQR: 3.7-7.4) in non-survivors (p <0.05). We observed that 88.2% of the non-survivors (at 30 days) required supplemental oxygen, 70.6% also needed advanced airway management and 94.1% needed intravenous medication (p <0.05 in all cases). The hospital admission rate was 53.2% (58 patients), with an ICU admission rate of 25.7% (p <0.05 in both cases).
Primary results
Eleven patients (10.1%) experienced early mortality before the first 48 hours after the index event, 14 patients (12.8%) within seven days and 17 patients (15.6%) within thirty days (see Table 1 ). The AUC of the PLA to discriminate mortality at different time points was 0.81 (95% CI 0.65-0.97) at 2 days, 0.83 (95% CI 0.70-0.97) at 7 days, 0.80 (95% CI 0.66-0.88) at 30 days and 0.77 (95% CI 0.66-0.88) for hospitalization in ICU, all of which reached statistical significance. The lactate value with greatest sensitivity and specificity to assess mortality at 2 days was 5.9 mmol/L. For determining mortality at 7 and 30 days, this value decreased to 4.1 mmol/L and for the assessment of ICU admission, to 4.9 mmol/L. Table 1 shows the values for sensitivity, specificity, PPV, NPV, PLR and NLR for these lactate values obtained in each case.
DISCUSSION
The obtained data suggests that PLA has an excellent capacity to predict mortality and the admission of patients with MI to the ICU, higher than that obtained in similar studies.7 The best lactate values for determining 2-day mortality and admission to the ICU are higher than those associated with mortality at 7 and 30 days, which can Table 1 . Cut-off points of sensitivity and specificity with best score (Youden index) in terms of mortality (2, 7 and 30 days) and admission to ICU for PLA. 
LIMITATIONS
We have used mortality from any cause before 2, 7 and 30 days as the main outcome variable, excluding deaths that occurred outside this time window. Prospective multicenter studies with adequate power will be necessary to validate the use of lactic acid in a prehospital context.
CONCLUSIONS
In the prehospital context, PEMS professionals must be able to discriminate highrisk patients in cases with time-dependent diseases.
We believe that an objective and structured evaluation should be the fundamental basis for the evaluation of critical patients, but the use of PLA can complement that clinical decision-making, providing the most efficient and appropriate response in the shortest possible time.
